PDF(Pubmed)
Abstract：
Giant cell arteritis and Takayasu arteritis are two types of primary large-vessel vasculitis (LVV). Although glucocorticoids (GC) are the standard treatment for LVV, the disease relapse rates are high. Recent clinical trials on biological disease-modifying anti-rheumatic drugs (bDMARDs) and Janus kinase (JAK) inhibitors have demonstrated their efficacy in reducing LVV relapse rates and GC dosages. However, the control of residual inflammation and degenerative alterations in the vessel wall remains an outstanding requirement in the clinical management of LVV. The analysis of immune cell phenotypes in patients with LVV may predict their response to treatment with bDMARDs and JAK inhibitors and guide their optimal use. In this mini-review, we focused on molecular markers, including the immune cell proportions and gene expression, in patients with LVV and in mouse models of LVV treated with bDMARDs and JAK inhibitors.
摘要：
巨细胞动脉炎和大动脉炎是两种类型的原发性大血管血管炎（LVV）。虽然糖皮质激素（GC）是LVV的标准治疗方法，疾病复发率很高。最近有关生物疾病改善抗风湿药（bDMARD）和Janus激酶（JAK）抑制剂的临床试验已经证明了它们在降低LVV复发率和GC剂量方面的功效。然而,在LVV的临床治疗中,控制残余炎症和血管壁的退行性改变仍然是一项突出的要求.LVV患者的免疫细胞表型分析可以预测他们对bDMARDs和JAK抑制剂治疗的反应，并指导其最佳使用。在这个小型审查中，我们专注于分子标记，包括免疫细胞比例和基因表达，在LVV患者和用bDMARDs和JAK抑制剂治疗的LVV小鼠模型中。
